JBC INTERFERin siRNA transfection reagent

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M108600200 on July 18, 2002

J. Biol. Chem., Vol. 277, Issue 38, 35150-35155, September 20, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/38/35150    most recent
M108600200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Estève, P. O.
Right arrow Articles by St-Pierre, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Estève, P. O.
Right arrow Articles by St-Pierre, Y.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Protein Kinase C-zeta Regulates Transcription of the Matrix Metalloproteinase-9 Gene Induced by IL-1 and TNF-alpha in Glioma Cells via NF-kappa B*

Pierre Olivier EstèveDagger §, Éric ChicoineDagger , Olivier RobledoDagger , Fawzi Aoudjit||, Albert DescoteauxDagger **, Edouard F. PotworowskiDagger , and Yves St-PierreDagger **DaggerDagger

From the || Centre de Recherches en Immunologie et Rheumatologie, CHUQ Pavillon CHUL, Université Laval, Ste-Foy, Québec G1V 4G2 and Dagger  INRS-Institut Armand-Frappier, Université du Québec, Laval, Québec H7V 1B7, Canada

Received for publication, September 6, 2001, and in revised form, June 11, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The regulation of matrix metalloproteinase-9 (MMP-9) expression in glioma cells is one of the key processes in tumor invasion through the brain extracellular matrix. Although some studies have demonstrated the implication of classic protein kinase C (PKC) isoforms in the regulation of MMP-9 production by phorbol esters or lipopolysaccharide, the involvement of specific PKC isoforms in the signaling pathways leading to MMP-9 expression by inflammatory cytokines remains unclear. Here we report that the atypical PKC-zeta isoform participates in the induction of MMP-9 expression by interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha ) in rat C6 glioma cells. Indeed, zymography and semi-quantitative reverse transcriptase-PCR analysis showed that pretreatment of C6 cells with PKC-zeta pseudosubstrate abolished MMP-9 activity and gene expression induced by IL-1 or TNF-alpha . Accordingly, IL-1 and TNF-alpha were able to induce PKC-zeta activity, as demonstrated by in vitro kinase assay using immunoprecipitated PKC-zeta . Furthermore, stable C6 clones overexpressing PKC-zeta , but not PKC-epsilon , displayed an up-regulation of MMP-9 constitutive expression as well as an increase of mmp-9 promoter activity. These processes were inhibited by an NF-kappa B-blocking peptide and completely prevented by NF-kappa B-binding site mutation in the mmp-9 promoter. Taken together, these results indicate that PKC-zeta plays a key role in the regulation of MMP-9 expression in C6 glioma cells through NF-kappa B.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Glioma cells have the ability to invade brain tissues by secreting matrix metalloproteinases (MMPs),1 a family of proteases able to degrade different components of the extracellular matrix including collagen, fibronectin, and proteoglycans. One of these MMPs, MMP-9, has received much attention as its expression correlates with the progression of glioma (1). Furthermore, MMP-9 seems to be essential for the invasiveness of glioma cells, as it was recently reported that the inhibition of MMP-9 expression by antisense gene transfer strongly reduced the invasion of glioblastoma cells in vitro and in vivo (2). Therefore, understanding the role of the molecules implicated in the signaling pathways leading to mmp-9 gene expression in glioma cells is important in order to identify new therapeutic targets.

Several studies (3-5) have focused on the implication of protein kinase C (PKCs) in the regulation of mmp-9 gene expression, most notably by testing the effect of phorbol 12-myristate 13-acetate (PMA) on different types of cells, including human glioma cells. Members of the PKC family are divided into the following three groups of isoenzymes: the conventional PKC isoforms, which are activated by calcium and diacylglycerol (alpha , beta I, beta II, and gamma ); the novel PKCs, which are activated by diacylglycerol but are calcium-insensitive (delta , epsilon , eta , and theta ); and the atypical PKCs, which are calcium- and diacylglycerol-insensitive (zeta  and iota /lambda ). Despite the fact that a large number of studies (5-7) have established a link between PKCs and MMP-9 expression using PKC inhibitors, very few studies have addressed the implication of specific PKC isoenzymes in the regulation of MMP-9. Although our group (8) has shown that a dominant-negative form of PKC-alpha potentiated the secretion of MMP-9 induced by lipopolysaccharide in the mouse macrophage cell line RAW 264.7, others (9) have shown that PKC-beta isoform is implicated in PMA-induced mmp-9 gene expression in human HL-60 myeloid leukemia cells. However, the involvement of specific PKC isoforms in the signaling pathways leading to MMP-9 expression by inflammatory cytokines remains unclear. In a previous study (10), however, we reported that the inflammatory cytokines, interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha ) but not PMA, were both able to induce MMP-9 expression in the rat C6 glioma cells, raising the possibility that atypical, PMA-independent PKC isoenzymes could be involved. Among the atypical PKC isoforms, PKC-zeta was of potential interest as its activation could be induced by IL-1 and TNF-alpha (11, 12). Moreover, PKC-zeta plays a critical role in the regulation of gene transcription via nuclear factor-kappa B (NF-kappa B) (13), a transcriptional factor required for mmp-9 gene expression (14).

In this work, we show that induction of MMP-9 expression by IL-1 or TNF-alpha in C6 glioma cells is inhibited by pretreatment with a PKC-zeta -specific inhibitory peptide (PKC-zeta PS) and that both IL-1 and TNF-alpha induce the activation of PKC-zeta in C6 cells. Furthermore, stable C6 transfectants overexpressing PKC-zeta isoenzyme, but not clones overexpressing the PKC-epsilon isoenzyme, display a constitutive expression of MMP-9 at the mRNA and protein levels. Transient transfection experiments using mmp-9 promoter constructs not only confirmed that PKC-zeta exerts its effect by increasing its transcriptional activity but also implicated NF-kappa B as a key regulator of MMP-9 expression by PKC-zeta .

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Reagents and Antibodies-- Reagents used were obtained from Sigma unless otherwise indicated. SN50 peptide inhibitor of NF-kappa B translocation and SN50M control peptide were obtained from Calbiochem. The myristoylated PKC-zeta pseudosubstrate peptide was obtained from Quality Controlled Biochemicals. Mouse recombinant IL-1 and TNF-alpha were purchased from Genzyme. The rabbit polyclonal anti-PKC-zeta antibody (Santa Cruz Biotechnology) or a mouse monoclonal anti-PKC-epsilon antibody (Transduction Laboratories) was used for Western blot analysis as well as sheep anti-rabbit or anti-mouse antibody conjugated to horseradish peroxidase (ICN Pharmaceuticals).

Cell Lines-- The rat C6 glioma cell line was obtained from the American type Culture Collection (ATCC). The cells and stable transfectants were grown in Ham's F-10 medium supplemented with 15% (v/v) horse serum, 2.5% fetal bovine serum, and 10 mM HEPES buffer (complete medium). All tissue culture reagents were purchased from Invitrogen. Routine testing showed the cells to be free of mycoplasma. For stimulation assays with mouse recombinant IL-1alpha or TNF-alpha , cells were trypsinized with a solution of 1 mM EDTA, 0.25% (w/v) trypsin, seeded at a density of 106 cells/ml in 12-well cluster plates, and incubated for 18 h at 37 °C in 5% CO2. Monolayers were then washed three times with phosphate-buffered saline and fresh serum-free medium containing the appropriate cytokine added at the indicated concentration. In some experiments, C6 cells or transfectants overexpressing PKC-zeta were pre-incubated for 1 h with a myristoylated PKC-zeta pseudosubstrate or the NF kappa B inhibitory peptide before IL-1 or TNF-alpha treatment. Assays using 3,-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) were performed to ensure that treatments with these peptides had no effect on cell viability. Unless otherwise indicated, supernatants were harvested after 18 h of stimulation and stored at -20 °C until assayed.

cDNAs and Expression Vectors-- Wild type human PKC-epsilon (15) and wild type mouse PKC-zeta cDNAs (16) were obtained from the ATCC. Both cDNAs were cloned into the EcoRI site of the expression vector pCIN-4 (17), and the resulting constructs were designated pCIN-PKC-epsilon and pCIN-PKC-zeta , respectively.

Transfection-- To obtain C6 stable transfectants constitutively overexpressing PKC-epsilon or PKC-zeta isoforms, transfection was carried out by electroporation with pCIN-PKC-epsilon or pCIN-PKC-zeta plasmids. Controls were generated using C6 cells transfected with the empty pCIN-4 vector alone. Electroporation was performed using the following parameters: 10 µg of linearized DNA per 4 × 106 cells in Ham's F-10 on ice; 960 microfarads; 300 V/0.4 cm. After 48 h of culture in complete medium, transfected cells were allowed to grow in complete medium containing 400 µg/ml of geneticin (Invitrogen) before individual colonies were picked and expanded into cell lines. Individual clones were then tested for expression of PKC-epsilon or PKC-zeta by Western blot analysis using antibodies as described below.

Western Blot Analysis-- Adherent cells were washed once with phosphate-buffered saline and homogenized in lysis buffer (50 mM Tris-HCl, pH 7.4, 1 mM EGTA, 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM NaF, 1% Nonidet P-40, 0.25% sodium deoxycholate, 1 mM Na3VO4, and 10% glycerol) containing a mixture of protease inhibitors (CompleteTM tablets from Roche Molecular Biochemicals). Protein concentrations were determined using the Bradford assay. Total protein (50 µg) were electrophoresed through a 10% SDS-polyacrylamide gel and were electrotransferred onto a nitrocellulose membrane (Amersham Biosciences), and blots were incubated with a rabbit polyclonal anti-PKC-zeta antibody or with a mouse monoclonal anti-PKC-epsilon antibody. Sheep anti-rabbit or anti-mouse antibody conjugated to horseradish peroxidase were used as secondary antibodies. The bands were visualized by the ECL system (Amersham Biosciences).

Zymography-- Zymography was performed in 10% polyacrylamide gels that had been cast in the presence of gelatin as described previously (10). Briefly, samples (100 µl) were lyophilized, resuspended in loading buffer, and without prior denaturation were run on a 7.5% SDS-polyacrylamide gel containing 0.5 mg/ml gelatin. After electrophoresis, gels were washed to remove SDS and incubated for 18 h at 37 °C in a renaturing buffer (50 mM Tris, 5 mM CaCl2, 0.02% NaN3, 1% Triton X-100). Gels were subsequently stained with Coomassie Brilliant Blue G-250 and destained in 30% methanol, 10% acetic acid (v/v) to detect gelatinase secretion. Gelatinase activity was measured in arbitrary units by quantitative analysis of negatively stained bands through computerized image analysis (Bio-Rad, model GS-670 densitometer).

RNA Isolation and RT-PCR Analysis-- Isolation of total cellular RNA was performed using the Trizol reagent (Invitrogen) according to the manufacturer's instructions. Aliquots of 2 µg of total cellular RNA were used for first strand cDNA synthesis in 20 µl of reaction volume using 100 units of SuperscriptTM II reverse transcriptase (Invitrogen). Primer pairs for rat MMP-9, mouse beta -actin, and GAPDH-specific amplification of cDNA (PCR Core Kit, Roche Molecular Biochemicals) were as follows: (5') primer 5'-TCCCTCTGAATAAAGTCGACA-3' and (3') primer 5'-AGGTGA ACAAGGTGGACCATG-3' for MMP-9; (5') primer 5'-CATGGATGACGATATCGCTGCGC-3' and (3') primer 5'-GCTGTCGCCACGCTCGGTCAGGATC-3' for mouse beta -actin; (5') primer 5'-CGGAGTCAACGGATTTGGTCGTAT-3' and (3') primer 5'-AGCCTTCTCCATGGTGGTGAA GAC-3' for GAPDH. The lengths of the MMP-9, beta -actin, and GAPDH amplicons were 848, 575, and 306 bp, respectively. PCR amplifications were performed on a MJ Research Thermal Cycler (model PTC-100TM) using the following program: step 1, 94 °C for 1 min; step 2, 58 °C for 2 min; step 3, 72 °C for 3 min. Thirty cycles were performed for the amplification of MMP-9 and 20 cycles for beta -actin or GAPDH. The amplification for each gene was in the linear curve. PCR products were visualized on 1.5% agarose gels stained by ethidium bromide and UV transillumination. Semiquantitative analysis was conducted using a computerized densitometric imager to obtain MMP-9/GAPDH or MMP-9/beta -actin ratios.

Measure of PKC-zeta Activity-- Measurement of PKC-zeta activity was performed essentially as described previously (18). Briefly, after stimulation of C6 cells by IL-1 or TNF-alpha for 10 min, cells were incubated for 30 min at 4 °C in lysis buffer containing 20 mM Tris-HCl, pH 7.5, 0.25 M sucrose, 1.2 mM EGTA, 20 mM beta -mercaptoethanol, 1 mM PMSF, 1 mM Na3VO4, 1 mM Na4P2O7, 1 mM NaF, protease inhibitors (Roche Molecular Biochemicals), 1% Triton X-100, 0.5% Nonidet P-40, and 150 mM NaCl. Aliquots of 500 µg of proteins were then incubated overnight at 4 °C with a PKC-zeta /lambda -specific rabbit polyclonal antibody (Santa Cruz Biotechnology), and immunoprecipitates were collected on protein G-Sepharose beads (Amersham Biosciences). The beads were washed three times by low speed centrifugation with the kinase buffer (50 mM Tris-HCl, pH 7.5, 5 mM MgCl2, 100 µM Na3VO4, 100 µM Na4P2O7, 1 mM NaF, and 100 µM PMSF). The immunoprecipitated PKC-zeta was resuspended in 50 µl of kinase buffer, and kinase assay was performed by adding 4 µg of phosphatidylserine, 50 µM ATP, 3 µCi of [gamma -32P]ATP (ICN Pharmaceuticals), and 40 µM of epsilon -peptide (Calbiochem-Novabiochem) for 10 min at 30 °C. Blank values were determined from incubations conducted in the presence of 100 µM PKC-zeta pseudosubstrate and were subtracted from total kinase activity to determine PKC-zeta -specific activity. The reaction was stopped by adding 100 µl of SDS buffer. Samples were boiled for 5 min and separated by SDS-PAGE using an 18% polyacrylamide gel. Dried gels were exposed to x-ray films (Konica Medical Film) at -80 °C. Quantitative measurements of phosphorylation of the epsilon -peptide was obtained by densitometry through computerized image analysis.

Cloning of mmp-9 Promoter and Transient Transfections-- A 737-bp fragment of the 5'-flanking region of the mmp-9 gene (-681 to +63), containing two Sp1 and one AP-1 and NF-kappa B-binding sites (all elements necessary for mmp-9 promoter activity) (14), was obtained by PCR amplification using stringent conditions on a genomic DNA isolated from 164T2 murine lymphoma cells (19), using the following primers: (5') primer 5'-AGGAAGGATAGTGCTAGCCTGAGAAGGATG-3' and (3') primer 5'-CCGAAACTCGAGGAGAGCCAGGAGCAGGG-3'. After sequencing (GenBankTM accession number AF403768), this fragment was cut by NheI and XhoI and subsequently subcloned into pGL-III Basic vector encoding for firefly luciferase (Promega) to generate pGL-MMP-9wt (wild type). Creation of a double-point mutation into the NF-kappa B-binding site (GGAATTCCCCC to GGAATTGGCCC) to generate pGL-MMP-9 Delta NF-kappa B was performed using the following (forward) primer: 5'-GGGTTGCCCCGTGGAATTGGCCCAAATCCTGC-3'. The mutant was generated using the Quick Change Site-directed Mutagenesis Kit (Stratagene). Transient transfections were performed using LipofectAMINE 2000 (Invitrogen) according to the manufacturer's instructions. Transfection efficiency was monitored by co-transfection with 0.5 µg of the pSV/beta -gal plasmid encoding for beta -galactosidase (Promega). Forty eight hours post-transfection, luciferase activity was measured using the Luciferase Assay System protocol (Promega) and a luminometer (Lumat LB 9507, Berthold). The beta -galactosidase activity was detected by a colorimetric enzyme assay using o-nitrophenyl-beta -D-galactopyranoside as a substrate. The ratio of luciferase activity to beta -galactosidase activity in each sample served as a measure of normalized luciferase activity.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The Induction of MMP-9 Activity and mRNA Expression by IL-1 or TNF-alpha Is Inhibited by the PKC-zeta Pseudosubstrate in C6 Glioma Cells-- We induced the secretion the 94-kDa precursor form of MMP-9 by IL-1 and TNF-alpha in the culture supernatant of C6 glioma cells and detected it by zymography (Fig. 1A) (10). To determine whether the induction of MMP-9 via these cytokines involved PKC-zeta , we attempted such an induction using a PKC-zeta -specific inhibitory peptide. This peptide, corresponding to the pseudosubstrate (PS) motif of atypical PKCs, suppresses PKC-zeta activity (20) by interacting with the substrate-binding pocket in the catalytic domain (21). Moreover, PKC pseudosubstrates, such as PKC-zeta -PS, specifically block PKC activation by inhibiting their phosphorylation (22, 23). Our results showed that preincubation of C6 cells with increasing doses of the peptide strongly inhibited the induction of MMP-9 by both IL-1 and TNF-alpha (Fig. 1A). The same PKC-zeta inhibitory peptide also reduced constitutive levels of MMP-9. Such a marked dose-dependent inhibition of secretion was specific to MMP-9, as the secretion of MMP-2 was not significantly altered by the incubation with the inhibitory peptide. The level of secretion of an unknown 97-kDa band, occasionally detected in C6 cell supernatants, was not affected by cell treatment with cytokines or upon treatment with the PKC-zeta pseudosubstrate.


View larger version (47K):
[in this window]
[in a new window]
  		Fig. 1.   Effect of a PKC-zeta pseudosubstrate on the induction of MMP-9 activity and mRNA expression by IL-1 or TNF-alpha in C6 cells. Rat C6 cells were treated with the PKC-zeta pseudosubstrate (PKC-zeta PS) at the indicated doses for 1 h and either stimulated or not stimulated (NS) with murine IL-1 (100 units/ml) or murine TNF-alpha (100 units/ml). After 18 h, supernatants were collected, lyophilized, and assayed for their gelatinase content by zymography (A). Molecular masses (kDa) appear on the left. At 10 h, total RNA was extracted. and RT-PCR analysis using MMP-9 and GAPDH-specific primers was performed as described under "Experimental Procedures" (B). Molecular weight markers are 100-bp ladder. Results are representative of three independent experiments. C, C6 cells were treated at the indicated dose of PKC-zeta pseudosubstrate (PKC-zeta PS) or the control peptide (protein kinase inhibitor (PKI14-22)) for 1 h before the stimulation with or without (NS) murine TNF-alpha (100 units/ml). After 18 h, supernatants were collected, lyophilized, and assayed for their gelatinase content by zymography. Results are representative of two independent experiments.

To determine whether indeed PKC-zeta was involved in the regulation of MMP-9 at the mRNA level, we next carried out a semi-quantitative RT-PCR. As expected, we found that, although the constitutive levels of MMP-9 mRNA in C6 cells were very low, both IL-1 and TNF-alpha induced a strong up-regulation of the levels of the same mRNA in these cells. Preincubation with the PKC-zeta -specific inhibitory peptide, however, strongly inhibited, in a dose-dependent manner, the induction of MMP-9 mRNA by these cytokines, whereas GAPDH mRNA levels remained unchanged (Fig. 1B). Taken together, these data indicate that PKC-zeta may be involved in the induction, by IL-1 and TNF-alpha , of mmp-9 gene expression.

IL-1 and TNF-alpha Induces PKC-zeta Activity in C6 Glioma Cells-- The above results were consistent with the idea that IL-1 and TNF-alpha are functionally linked with the activation of PKC-zeta . To test for this hypothesis, we investigated whether stimulation of C6 cells via these cytokines induced PKC-zeta enzymatic activity. By using in vitro kinase assays on PKC-zeta immunoprecipitates obtained from resting or cytokine-stimulated cells, we first found that stimulation of C6 cells with both cytokines increased the kinase activity associated with the PKC-zeta immunoprecipitates (Fig. 2, A and B). Most importantly, incubation with the PKC-zeta pseudosubstrate inhibited both TNF-alpha - and IL-1-induced kinase activity by 50 (p < 0.01) and 60% (p < 0.02) below the control levels, respectively, although it had no effect on the constitutive levels of unstimulated cells, supporting the hypothesis that IL-1 and TNF-alpha can both induce PKC-zeta activity.


View larger version (27K):
[in this window]
[in a new window]
  		Fig. 2.   Induction of PKC-zeta activity by IL-1 and TNF-alpha . A, rat C6 cells were either stimulated for 10 min or not stimulated (NS) with murine IL-1 (100 units/ml) or murine TNF-alpha (100 units/ml). After immunoprecipitation of total cell lysates with a PKC-zeta /lambda antibody, an in vitro kinase assay was performed in the absence (-) or in presence (+) of PKC-zeta PS (100 µM) as indicated under "Experimental Procedures." Phosphorylation of epsilon -peptide was detected by autoradiography. B, quantitative analyses of epsilon -peptide phosphorylation were performed by imaging densitometry. The histogram represents the means of two independent experiments as shown in A. Statistical analysis were carried out using Student's t test for unpaired samples. *, p < 0.01; **, p < 0.02.

Overexpression of PKC-zeta , but Not PKC-epsilon , Up-regulates MMP-9 Expression-- As another approach to test the implication of PKC-zeta in the regulation of MMP-9 expression, we transfected C6 cells with a plasmid encoding PKC-zeta , and we selected three independent stable clones (zeta 1, zeta 2, and zeta 3) expressing high levels of this isoform (Fig. 3A). Gelatin zymography of conditioned media isolated from clones zeta 1, zeta 2, and zeta 3 showed that overexpression of PKC-zeta in all three clones induced an up-regulation of MMP-9 activity in C6 cells (Fig. 3B). No such effect was observed with C6 cells transfected with the empty vector. Overexpression of MMP-9 upon transfection of PKC-zeta was concomitant to the generation of an unidentified 58-kDa gelatinolytic band, corresponding to the activation of the 62-kDa form of MMP-2. MMP-2 was not, however, expressed at the mRNA level in C6 cells or its transfectants (data not shown). Furthermore, the fact that the levels of mRNA in the PKC-zeta transfectants were higher than those found in the control transfectants (Fig. 3C) confirmed the idea that the constitutive levels of MMP-9 observed in PKC-zeta transfectants were indeed regulated at the mRNA level.


View larger version (24K):
[in this window]
[in a new window]
  		Fig. 3.   Overexpression of PKC-zeta , but not of PKC-epsilon , induces MMP-9 activity and gene expression. Stable clones (zeta 1, zeta 2, and zeta 3) overexpressing PKC-zeta (A) and PKC-epsilon (epsilon 1, epsilon 2, and epsilon 3, D) were characterized by Western blot analysis compared with C6 cells transfected with the vector alone (V1 for PKC-zeta , and V1, V2 for PKC-epsilon , respectively). Clones zeta 1, zeta 2, zeta 3 and V1, V2, epsilon 1, epsilon 2, and epsilon 3 were either stimulated or not stimulated (NS) with murine IL-1 (100 units/ml) or with murine TNF-alpha (100 units/ml). After 18 h, supernatants were collected, lyophilized, and assayed for their gelatinase content by zymography (B and E, respectively). Total RNA isolated from V1, V2, zeta 1, and zeta 2 clones was assayed for RT-PCR analysis by using MMP-9 and beta -actin-specific primers (C). Results are representative of three independent experiments.

To determine whether the effect of PKC-zeta on the regulation of MMP-9 was specific, we selected three stable transfectants (epsilon 1, epsilon 2, and epsilon 3) overexpressing PKC-epsilon (Fig. 3D). Two stable clones (V1 and V2) transfected with the empty vector (no cDNA insert) were used as controls. We found that overexpression of PKC-epsilon had no effect on expression of MMP-9 (Fig. 3E), suggesting that the regulation of MMP-9 by PKC-zeta is isoform-specific.

MMP-9 Induction in C6 Cells or in Clones Overexpressing PKC-zeta Is NF-kappa B-dependent-- Up-regulation of mmp-9 gene expression upon exposure to inflammatory cytokines critically depends on the activation of NF-kappa B (24, 25). To evaluate the possible implication of this transcription factor in the regulation of MMP-9 by PKC-zeta , we tested the effect of an NF-kappa B-specific inhibitory peptide, SN50, that blocks its translocation to the nucleus (26). Our results showed that this peptide strongly inhibited, in a dose-dependent manner, the secretion of MMP-9 induced by IL-1 or TNF-alpha in C6 cells (Fig. 4). In a control experiment, the mutant peptide (SN50M) failed to inhibit the secretion of MMP-9. Furthermore, addition of SN50, but not of the control peptide, decreased the constitutive level of MMP-9 activity in both zeta 1 and zeta 2 clones (Fig. 4B). These results were confirmed by semi-quantitative RT-PCR analysis (data not shown). These data therefore indicate that NF-kappa B participates in the induction of MMP-9 expression mediated by PKC-zeta .


View larger version (67K):
[in this window]
[in a new window]
  		Fig. 4.   MMP-9 induction, either by cytokines or in PKC-zeta clones, is inhibited by the SN50 NF-kappa B-blocking peptide. A, rat C6 cells were treated with or without (-), 50 (+), or 100 (++) µg/ml of the SN50 or SN50M peptide for 1 h before being stimulated or not (NS) by murine IL-1 (100 units/ml) or by murine TNF-alpha (100 units/ml). After 18 h, supernatants were collected, lyophilized, and assayed for their gelatinase content by zymography. B, V1, zeta 1, and zeta 2 clones were incubated with or without (-) 100 µg/ml of SN50 or of SN50M (+) peptide, and after 18 h, their supernatants were collected, lyophilized, and assayed for their gelatinase content by zymography. Results are representative of three independent experiments.

mmp-9 Promoter Activity Is Up-regulated by PKC-zeta through NF-kappa B-- Finally, to further establish that the up-regulation of MMP-9 expression in zeta 1 and zeta 2 clones depended on its promoter activity through a NF-kappa B-dependent mechanism, we used reporter gene constructs containing the mmp-9 promoter harboring a double mutation into the NF-kappa B-binding site. Transient transfections with pGL-MMP-9wt in V1, zeta 1, and zeta 2 clones demonstrated a 1.5- and 2-fold increase in MMP-9 transcriptional promoter activity in zeta 1 and zeta 2 clones, respectively, when compared with the V1 clone (Fig. 5). This induction was completely prevented by the double mutation C right-arrow G into the NF-kappa B-binding site of mmp-9 promoter. In addition, treatment of V1 clone with IL-1 or TNF-alpha also induced a 2-fold increase of mmp-9 promoter activity, which was consistent with the results of Eberhardt et al. (24) and was abolished by the mutation into the NF-kappa B-binding site. Taken together, these data indicate that NF-kappa B is essential for the up-regulation of mmp-9 promoter activity by either PKC-zeta or cytokines, IL-1, and TNF-alpha .


View larger version (19K):
[in this window]
[in a new window]
  		Fig. 5.   Increase of mmp-9 promoter activity, either by cytokines or in PKC-zeta clones, is inhibited by mutation into the NF-kappa B-binding site. V1, zeta 1, and zeta 2 clones cultured in 6-well plates were cotransfected with 4 µg of pGL-Basic, pGL-MMP-9wt, or pGL-MMP-9-Delta NF-kappa B, and 0.5 µg of pSV/beta -gal. Six hours after transfection, cells were treated with (+) or without (-) 100 units/ml of IL-1 or TNF-alpha for 48 h. Values of luciferase activities were corrected for transfection efficiencies by assaying for beta -galactosidase activity. The histogram shows the means ± S.E. of two independent experiments performed in duplicate. Statistical analysis was carried out using Student's t test for unpaired samples. *, p < 0.05; **; p < 0.02, ***; p < 0.005.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In the present study, we have shown that the atypical PKC isoenzyme PKC-zeta plays a critical role in mediating the IL-1- and TNF-alpha -dependent production of MMP-9 in C6 glioma cells through the downstream activation of NF-kappa B. Specifically, we showed the following: 1) up-regulation of MMP-9 expression at the mRNA and protein levels by IL-1 and TNF-alpha is inhibited by a PKC-zeta -specific blocking peptide; 2) both cytokines activates PKC-zeta ; 3) overexpression of PKC-zeta , but not of PKC-epsilon , induces expression of the MMP-9 at the mRNA and protein levels; 4) addition of an NF-kappa B-blocking peptide, but not of a control peptide, inhibits MMP-9-induced expression in C6 cells or PKC-zeta transfectants; and 5) transient transfection experiments established that the up-regulation of the mmp-9 promoter activity in cells overexpressing PKC-zeta was completely abolished by mutation in NF-kappa B-binding site.

In a previous publication (10), we had reported that IL-1 and TNF-alpha , but not PMA, were able to induce expression of MMP-9 in the rat C6 glioma cells. In the present work, we now identify PKC-zeta , a PMA-insensitive isoenzyme, as a key regulator of mmp-9 gene expression in C6 cells. Moreover, our data further establish a functional link between PKC-zeta , IL-1, TNF-alpha , and the activation of NF-kappa B, a transcription factor necessary for up-regulation of MMP-9 expression (12). This implication of NF-kappa B and PKC-zeta in the induction of MMP-9 by IL-1 and TNF-alpha likely results from the activation of Ikappa B kinase by PKC-zeta (27), which in turn induces, upon phosphorylation, the dissociation of the negative regulator Ikappa B-alpha from NF-kappa B (28). In addition, PKC-zeta can be involved in the phosphorylation of RelA, a subunit of NF-kappa B, which leads to an increase of its transcriptional activity (29). In fact, our observation that the induction of MMP-9 by IL-1 or TNF-alpha was completely abolished by pretreatment with an NF-kappa B-specific inhibitory peptide, which acts by blocking translocation of NF-kappa B to the nucleus, strongly supports the idea that MMP-9 induction by these cytokines is mainly NF-kappa B-dependent. However, this peptide failed to achieve the same level of inhibition with the clones overexpressing PKC-zeta . This could be attributed to the high levels of the activated forms of the isoenzymes. In addition to NF-kappa B which is necessary but not sufficient to up-regulate MMP-9, the previous demonstration that the activating protein-1 (AP-1) plays an essential role in the transcription of the mmp-9 gene (12) further supports an association between PKC-zeta and AP-1. Such an increase in the AP-1 binding activity could be the result of an increase of c-jun protooncogene mRNA levels, a mechanism previously observed in transfected U937 cells stably overexpressing PKC-zeta (30). Because both AP-1 and NF-kappa B can be regulated by mitogen-activated protein kinases (31, 32) which can be activated by PKC-zeta (33, 34), it will be of interest to investigate the implication of these molecules in the signaling cascade leading to the up-regulation of MMP-9 in C6 clones overexpressing PKC-zeta . A case in point would be p38, a mitogen-activated protein kinase recently identified as being involved in the regulation of MMP-9 upon stimulation by IL-1 and TNF-alpha in C6 cells (35).

We found that IL-1 and TNF-alpha were able to stimulate PKC-zeta activity in C6 glioma cells. Such an activation of PKC-zeta by these cytokines has been reported previously (11, 12) in other cell types, most notably in U937, rhabdomyosarcoma, and bladder-derived carcinoma cells. Among the putative second messengers that could mediate the activation of PKC-zeta upon stimulation with IL-1 and TNF-alpha are Ras or ceramide (36, 37), both of which having been shown to be potent activator of PKC-zeta . The implication phosphatidylinositol 3-kinase (PI-3K), another activator of PKC-zeta (38), however, is unlikely as treatment of IL-1 or TNF-alpha -stimulated C6 cells with wortmannin, a PI 3-kinase inhibitor, has been shown to potentiate the induction of MMP-9,2 suggesting that PI 3-kinase may rather act as a negative regulator of MMP-9. A similar role for this kinase has recently been assigned in the case of the nitric-oxide synthase gene following induction by IL-1 in C6 cells (39), suggesting that both genes are regulated through a common signaling pathway. In support of this notion, C6-ceramide and p21Ras have been shown to be involved in the induction of nitric-oxide synthase expression by IL-1 or TNF-alpha through NF-kappa B in C6 cells and in rat primary astrocytes (40, 41). Further investigations on the early events in the signaling cascade leading the activation of PKC-zeta by IL-1 and TNF-alpha should clarify this issue.

It is noteworthy that we have observed a low but reproducible decrease of MMP-2 activation upon addition of the SN50 peptide but not the control peptide. Other investigators (42) have also reported SN50 can block activation of MMP-2, most notably in dermal fibroblasts, and attributed its effect to its ability to block the NF-kappa B signaling pathway that leads to the induction of MT1-MMP. Whether MT1-MMP is implicated in the activation of MMP-2 in glioma cells is under investigation

In conclusion, we showed that PKC-zeta is directly involved in the signaling cascade that controls the transcription of the mmp-9 gene via the NF-kappa B-dependent pathway in the C6 glioma cells. Accumulating evidence indicates that MMP-9 contributes not only to tumor invasion but also to the degradation of the blood-brain barrier, to neurodegenerative processes, and to angiogenesis (43-45), three common features associated with glial tumors. In vivo studies, using the C6 cells and PKC-zeta -blocking agent, need to be done in order to validate the in vitro finding and establish whether PKC antagonists can be envisaged in the therapy of glioma-derived tumors.

    ACKNOWLEDGEMENTS

We thank Anna-Karine Bélizaire and Benoit Ochietti for help in preparing this manuscript.

    FOOTNOTES

* This work was supported in part by the National Cancer Institute of Canada (to  Y. S. P. and E. F. P.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Present address: New England Biolabs, 32 Tozer Rd., Beverly, MA 01915.

Supported by a postdoctoral fellowship from la Fondation Armand-Frappier.

** Scholars of the Fonds de la Recherche en Santé du Québec.

Dagger Dagger To whom correspondence should be addressed: INRS-Institut Armand-Frappier, 531 Boul. des-Prairies, Laval, Québec H7V 1B7, Canada. Tel.: 514-686-5354; Fax: 514-686-5501; E-mail: yves.st-pierre@inrs-iaf.uquebec.ca.

Published, JBC Papers in Press, July 18, 2002, DOI 10.1074/jbc.M108600200

2 P. O. Estève and Y. St-Pierre, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: MMPs, matrix metalloproteinases; PKC, protein kinase C; IL-1, interleukin-1; TNF-alpha , tumor necrosis factor-alpha ; PKC-zeta PS, PKC-zeta pseudosubstrate; PMA, phorbol 12-myristate 13-acetate; NF-kappa B, nuclear factor-kappa B; PMSF, phenylmethylsulfonyl fluoride; AP-1, activating protein-1; PI-3 kinase, phosphatidylinositol 3-kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RT, reverse transcriptase; wt, wild type.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Rao, J. S., Steck, P. A., Mohanam, S., Stetler-Stevenson, W. G., Liotta, L. A., and Sawaya, R. (1993) Cancer Res. 53, 2208-2211[Abstract/Free Full Text]
2. Kondraganti, S., Mohanam, S., Chintala, S. K., Kin, Y., Jasti, S. L., Nirmala, C., Lakka, S. S., Adachi, Y., Kyritsis, A. P., Ali-Osman, F., Sawaya, R., Fuller, G. N., and Rao, J. S. (2000) Cancer Res. 60, 6851-6855[Abstract/Free Full Text]
3. Juarez, J., Clayman, G., Nakajima, M., Tanakabe, K. K., Saya, H., Nicolson, G. L., and Boyd, D. (1993) Int. J. Cancer 55, 10-18[Medline] [Order article via Infotrieve]
4. Fabunmi, R. P., Baker, A. H., Murray, E. J., Booth, R. F., and Newby, A. C. (1996) Biochem. J. 315, 335-342[Medline] [Order article via Infotrieve]
5. Chintala, S. K., Sawaya, R., Aggarwal, B. B., Majumder, S., Giri, D. K., Kyritsis, A. P., Gokaslan, Z. L., and Rao, J. S. (1998) J. Biol. Chem. 273, 13545-13551[Abstract/Free Full Text]
6. Segain, J. P., Harb, J., Gregoire, M., Meflah, K., and Menanteau, J. (1996) Cancer Res. 56, 5506-5512[Abstract/Free Full Text]
7. Xie, B., Dong, Z., and Fidler, I. J. (1994) J. Immunol. 152, 3637-3644[Abstract]
8. St-Denis, A., Chano, F., Tremblay, P., St-, Pierre, Y., and Descoteaux, A. (1998) J. Biol. Chem. 273, 32787-32792[Abstract/Free Full Text]
9. Xie, B., Laouar, A., and Huberman, E. (1998) J. Biol. Chem. 273, 11576-11582[Abstract/Free Full Text]
10. Esteve, P. O., Tremblay, P., Houde, M., St-, Pierre, Y., and Mandeville, R. (1998) Biochim. Biophys. Acta 1403, 85-96[Medline] [Order article via Infotrieve]
11. Muller, G., Ayoub, M., Storz, P., Rennecke, J., Fabbro, D., and Pfizenmaier, K. (1995) EMBO J. 14, 1961-1969[Medline] [Order article via Infotrieve]
12. Limatola, C., Barabino, B., Nista, A., and Santoni, A. (1997) Biochem. J. 321, 497-501[Medline] [Order article via Infotrieve]
13. Diaz-Meco, M. T., Berra, E., Municio, M. M., Sanz, L., Lozano, J., Dominguez, I., Diaz-Golpe, V., Lain de Lera, M. T., Alcami, J., Paya, C. V., Arenzana-Seisdedos, F., Virelizier, J.-L., and Moscat, J. (1993) Mol. Cell. Biol. 13, 4770-4775[Abstract/Free Full Text]
14. Sato, H., and Seiki, M. (1993) Oncogene 8, 395-405[Medline] [Order article via Infotrieve]
15. Basta, P., Strickland, M. B., Holmes, W., Loomis, C. R., Ballas, L. M., and Burns, D. J. (1992) Biochim. Biophys. Acta 1132, 154-160[Medline] [Order article via Infotrieve]
16. Goodnight, J., Kazanietz, M. G., Blumberg, P. M., Mushinski, J. F., and Mischak, H. (1992) Gene (Amst.) 122, 305-311[CrossRef][Medline] [Order article via Infotrieve]
17. Rees, S., Coote, J., Stables, J., Goodson, S., Harris, S., and Lee, M. G. (1996) BioTechniques 20, 102-104[Medline] [Order article via Infotrieve]
18. Bandyopadhyay, G., Standaert, M. L., Zhao, L., Yu, B., Avignon, A. M., Galloway, L., Karnam, P., Moscat, J., and Farese, R. V. (1997) J. Biol. Chem. 272, 2551-2558[Abstract/Free Full Text]
19. Aoudjit, F., Potworowski, E. F., and St-Pierre, Y. (1998) Blood 91, 623-629[Abstract/Free Full Text]
20. Zhou, G., Lamar Seibenhener, M., and Wooten, M. W. (1997) J. Biol. Chem. 272, 31130-31137[Abstract/Free Full Text]
21. House, C., and Kemp, B. E. (1987) Science 238, 1726-1728[Abstract/Free Full Text]
22. Standaert, M. L., Galloway, L., Karnam, P., Bandyopadhyay, G., Moscat, J., and Farese, R. V. (1997) J. Biol. Chem. 272, 30075-30082[Abstract/Free Full Text]
23. Dutil, E. M., and Newton, A. C. (2000) J. Biol. Chem. 275, 10697-10701[Abstract/Free Full Text]
24. Eberhardt, W., Huwiler, A., Beck, K. F., Walpen, S., and Pfeilschifter, J. (2000) J. Immunol. 165, 5788-5797[Abstract/Free Full Text]
25. Yokoo, T., and Kitamura, M. (1996) Am. J. Physiol. 270, F123-F130[Medline] [Order article via Infotrieve]
26. Lin, Y. Z., Yao, S. Y., Veach, R. A., Torgerson, T. R., and Hawiger, J. (1995) J. Biol. Chem. 270, 14255-14258[Abstract/Free Full Text]
27. Diaz-Meco, M. T., Dominguez, I., Sanz, L., Dent, P., Lozano, J., Municio, M. M., Berra, E., Hay, R. T., Sturgill, T. W., and Moscat, J. (1994) EMBO J. 13, 2842-2848[Medline] [Order article via Infotrieve]
28. DiDonato, J. A., Hayakawa, M., Rothwarf, D. M., Zandi, E., and Karin, M. (1997) Nature 388, 548-554[CrossRef][Medline] [Order article via Infotrieve]
29. Anrather, J., Csizmadia, V., Soares, M. P., and Winkler, H. (1999) J. Biol. Chem. 274, 13594-13603[Abstract/Free Full Text]
30. Ways, D. K., Posekany, K., deVente, J., Garris, T., Chen, J., Hooker, J., Qin, W., Cook, P., Fletcher, D., and Parker, P. (1994) Cell Growth Differ. 5, 1195-1203[Abstract]
31. Karin, M. (1995) J. Biol. Chem. 270, 16483-16486[Free Full Text]
32. Beyaert, R., Cuenda, A., Vanden, B. W., Plaisance, S., Lee, J. C., Haegeman, G., Cohen, P., and Fiers, W. (1996) EMBO J. 15, 1914-1923[Medline] [Order article via Infotrieve]
33. Berra, E., Diaz-Meco, M. T., Lozano, J., Frutos, S., Municio, M. M., Sanchez, P., Sanz, L., and Moscat, J. (1995) EMBO J. 14, 6157-6163[Medline] [Order article via Infotrieve]
34. Takeda, H., Matozaki, T., Takada, T., Noguchi, T., Yamao, T., Tsuda, M., Ochi, F., Fukunaga, K., Inagaki, K., and Kasuga, M. (1999) EMBO J. 18, 386-395[CrossRef][Medline] [Order article via Infotrieve]
35. Missé, D., Esteve, P. O., Rennenboog, B., Vidal, M., Cerutti, M., St-, Pierre, Y., Yssel, H., Parmentier, M., and Veas, F. (2001) Blood 98, 541-547[Abstract/Free Full Text]
36. Diaz-Meco, M. T., Lozano, J., Municio, M. M., Berra, E., Trutos, S., Sanz, L., and Moscat, J. (1994) J. Biol. Chem. 269, 31706-31710[Abstract/Free Full Text]
37. Bourbon, N. A., Yun, J., and Kester, M. (2000) J. Biol. Chem. 275, 35617-35623[Abstract/Free Full Text]
38. Nakanishi, H., Brewer, K. A., and Exton, J. H. (1993) J. Biol. Chem. 268, 13-16[Abstract/Free Full Text]
39. Pahan, K., Raymond, J. R., and Singh, I. (1999) J. Biol. Chem. 274, 7528-7536[Abstract/Free Full Text]
40. Pahan, K., Sheikh, F. G., Khan, M., Namboodiri, A. M. S., and Singh, I. (1998) J. Biol. Chem. 273, 2591-2600[Abstract/Free Full Text]
41. Pahan, K., Liu, X., McKinney, M. J., Wood, C., Sheikh, F. G., and Raymond, J. R. (2000) J. Neurochem. 74, 2288-2295[CrossRef][Medline] [Order article via Infotrieve]
42. Han, Y. P., Tuan, T. L., Wu, H., Hughes, M., and Garner, W. L. (2001) J. Cell Sci. 114, 131-139[Abstract]
43. Rosenberg, G. A., Estrada, E. Y., Dencoff, J. E., and Stetler-Stevenson, W. G. (1995) Brain Res. 703, 151-155[CrossRef][Medline] [Order article via Infotrieve]
44. Proost, P., Van Damme, J., and Opdenakker, G. (1993) Biochem. Biophys. Res. Commun. 192, 1175-1181[CrossRef][Medline] [Order article via Infotrieve]
45. Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Kazuhiko, T., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., and Hanahan, D. (2000) Nat. Cell Biol. 2, 737-744[CrossRef][Medline] [Order article via Infotrieve]

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Mol Cancer ResHome page
G. Sethi, K. S. Ahn, and B. B. Aggarwal
Targeting Nuclear Factor-{kappa}B Activation Pathway by Thymoquinone: Role in Suppression of Antiapoptotic Gene Products and Enhancement of Apoptosis
Mol. Cancer Res., June 1, 2008; 6(6): 1059 - 1070.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
G. Sethi, K. S. Ahn, B. Sung, and B. B. Aggarwal
Pinitol targets nuclear factor-{kappa}B activation pathway leading to inhibition of gene products associated with proliferation, apoptosis, invasion, and angiogenesis
Mol. Cancer Ther.,